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ABSTRACT 
 
Background & purpose   The P2X3 receptor is an ATP-gated ion channel expressed by sensory 
afferent neurons, and is as a target to treat chronic sensitisation conditions.  The first-in-class, 
selective P2X3 and P2X2/3 receptor antagonist, the diaminopyrimidine MK-7264 
(Gefapixant), has progressed to Phase III trials for refractory or unexplained chronic cough. 
We have used patch-clamp to elucidate the pharmacology and kinetics of MK-7264 and rat 
models of hypersensitivity and hyperalgesia to test efficacy in these conditions.  
 
Experimental approach Whole-cell patch-clamp of 1321N1 cells expressing human P2X3 and 
P2X2/3 receptors was used to determine mode of MK-7264 action, potency and kinetics. The 
analgesic efficacy was assessed using paw withdrawal threshold and limb weight distribution 
in rat models of inflammatory, osteoarthritic and neuropathic sensitisation. 
 
Key results MK-7264 is a reversible allosteric antagonist at human P2X3 and P2X2/3 receptors 
with IC50 values of 153 and 220nM, respectively.  Experiments with the slowly desensitising 
P2X2/3 heteromer revealed concentration and state-dependency to wash-on, with faster rates 
and greater inhibition when applied before agonist compared to during agonist application.  
Wash-on rate ( value) for MK-7264 at maximal concentrations was 19s and 146s when applied 
before and during agonist application, respectively.  In vivo, MK-7264 (30 mg/kg) displayed 
efficacy comparable to naproxen (20 mg/kg) in inflammatory and osteoarthritic sensitisation 
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models, and gabapentin (100 mg/kg) in neuropathic sensitisation models, increasing  paw 
withdrawal threshold and decreasing weight bearing discomfort.     
 
Conclusions and implications MK-7264 is a reversible and selective P2X3 and P2X2/3 
antagonist, exerting allosteric antagonism via preferential activity at closed channels. Efficacy 
in rat models supports clinical investigation of chronic sensitisation conditions. 
 
ABBREVIATIONS ATP: adenosine 5’-trisphophate; meATP; ,-methylene adenosine 
5’-trisphophate 
 
BULLET POINT SUMMARY 
 
What is already known?   
 
P2X3 is an ATP-gated ion channel expressed on sensory neurons.  The antagonist MK-7264 
has shown efficacy in a Phase 2b clinical trial for unexplained or refractory chronic cough. 
 
What this study adds 
 
This study reveals the mechanism of action of MK-7264 at human P2X3 and P2X2/3 receptors, 
and in vivo efficacy in pre-clinical models of sensitisation. 
 
Clinical significance 
 
MK-7264 has progressed to a Phase 3 trial for unexplained or refractory chronic cough, and 
has the potential to be clinically useful for conditions involving sensitisation. 
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INTRODUCTION 
 
P2X receptors are a family of trimeric, ATP-gated ion channels (North, 2002).  The human 
genome encodes seven pore-forming subunits (P2X1-7), that are capable of assembling as 
homomeric and heteromeric receptors in a subunit-dependent fashion (Surprenant & North, 
2009).  Each subunit has a double transmembrane topology and large extracellular domain 
which forms the orthosteric ATP binding site with an adjacent subunit  (Kawate et al., 2009; 
Mansoor et al., 2016; Wang et al., 2018).  Several P2X receptor subtypes are implicated in 
pain, irritation and hypersensitivity and have been proposed as drug targets, including the P2X3 
receptor and P2X2/3 heteromeric receptor (Jarvis et al., 2002; Gever et al., 2010; Pijacka et al., 
2016; Stokes et al., 2017).  P2X3 receptor tissue expression is very limited with protein and 
mRNA transcript detected in small diameter C-fiber sensory neurons (Chen et al., 1995; Lewis 
et al., 1995; Xiang et al., 1998), particularly those innervating the skin and viscera (Bradbury 
et al., 1998), petrosal neurons and the carotid body afferents (Pijacka et al., 2016).  P2X3 and 
P2X2/P2X3 double knockout mice display reduced nocifensive responses to ATP and formalin 
injection, as well as bladder hyporeflexia (Cockayne et al., 2000; Cockayne et al., 2005), and 
both dorsal root and nodose ganglia neurons lose sensitivity to the selective agonist 
meATP(Zhong et al., 2001).  P2X3 expression increases in rat models of inferior alveolar 
nerve injury (Eriksson et al., 1998), complete Freund’s adjuvant-induced monoarthritis 
(Shinoda et al., 2005) and cast immobilisation (Sekino et al., 2014).  In rat models, the number 
of P2X3-positive small diameter L4 and L5 dorsal root ganglion neurons increases after chronic 
constriction of the sciatic nerve (Novakovic et al., 1999) but decreases following axotomy 
(Bradbury et al., 1998).  In humans, P2X3 expression is increased in bladder urothelium during 
interstitial cystitis (Tempest et al., 2004), endometriosis endometrium and endometriosis 
lesions (Ding et al., 2017). 
 
Studies in knockout mice (Cockayne et al., 2000; Cockayne et al., 2005) as well as RNAi 
(Barclay et al., 2002; Honore et al., 2002), small molecule antagonists (Jarvis et al., 2002; 
McGaraughty et al., 2003; Kaan et al., 2010), the spider venom peptide purotoxin-1 (Grishin 
et al., 2010) and blocking monoclonal antibodies (Shcherbatko et al., 2016) have all 
demonstrated the efficacy of P2X3 and P2X2/3 antagonism to reduce nocifensive responses, 
and neuropathic, inflammatory, arthritic and visceral pain.  Such studies validate P2X3 as a 
therapeutic target for chronic sensitisation conditions. 
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P2X3 and P2X2/3 receptors are antagonised by a range of molecules with poor selectivity and 
potency, including suramin, pyridoxal phosphate-6-azo (benzene-2,4-disulphonic acid) 
(PPADS) and reactive blue 2, in addition to 2’,3’-O-(2,4,6-trinitrophenyl) ATP (TNP-ATP) 
which has low metabolic stability (North, 2002).  Such molecules are therefore compromised 
for in vivo investigation (Jarvis et al., 2001; Ueno et al., 2003).  A-317491 (Jarvis et al., 2002), 
a more potent and selective P2X3 and P2X2/3 antagonist has been developed, however this 
molecule suffers from several undesirable characteristics including low oral bioavailability and 
very high protein binding (>99.9%). MK-7264 (formerly AF-219) is diaminopyrimidine 
antagonist of human P2X3 and P2X2/3 receptors.  The compound has reached Phase 2 proof 
of concept trials for pain in osteoarthritis of the knee and interstitial cystitis/bladder pain (Ford 
and Undhem, 2013) and Phase 2b trials for refractory chronic cough (Abdulqawi et al., 2015) 
whereby daytime cough frequency was significantly reduced compared to placebo.  MK-7264 
is the first-in-class selective P2X3 antagonist, named Gefapixant, and has progressed to a Phase 
3 trial for unexplained or refractory chronic cough (NCT03449134).  This drug is peripherally 
restricted but the close structural analogue, AF-353 is able to traverse the blood-brain barrier 
(Gever et al., 2010).  Though the mechanisms underlying chronic cough are not fully 
understood, it is widely accepted that heightened sensitivity of afferent limb of the cough reflex 
plays an important role in the disease (Higenbottam, 2002).  The efficacy of P2X3 antagonists 
as anti-tussive agents in humans is likely due to the blockade of P2X3 receptors expressed on 
the sensory neurons within the afferent limb of the cough reflex (Ford, 2012). Mice and rats 
lack a cough reflex and are therefore not useful in studying the efficacy of P2X3 antagonists as 
anti-tussive agents in vivo (Mazzone, 2005).  However, these preclinical models are useful in 
studying the in vivo effects of P2X3 receptor in other processes that involve afferent 
sensitisation and hyperalgesia. Here we electrophysiologically characterise MK-7264 at human 
P2X3 and P2X2/3 receptors and determine in vivo efficacy in rat models of sensitisation. 
 
MATERIALS AND METHODS 
 
Study ethics 
 
All animal experiments were performed at Pharmaron (Beijing, China).  Experiments were 
performed according to the guidelines approved by the Institutional Animal Care and Use 
Committee (IACUC) of Pharmaron following the guidance of the Association for Assessment 
and Accreditation of Laboratory Animal Care International (AAALAC). 
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Drugs and salts 
 
All basic salts, ATP, sodium carboxymethyl cellulose, gabapentin, naproxen and mono-
iodoacetic acid were purchased from Sigma.  Complete Freund’s adjuvant was purchased from 
Chondrex. meATPwas purchased from Tocris.  For electrophysiological studies, all drugs 
were dissolved in DMSO, with the final DMSO concentration of 0.1% (v/v) in all experiments.  
For in vivo studies, all drugs were dissolved in 0.5% (w/v) sodium carboxymethyl cellulose 
and administered orally at a volume of 5mL/kg. 
 
Cells 
 
1321N1 astrocytoma lines (RRID:CVCL_0110) stably transfected with human P2X2, P2X3 or 
co-expressing P2X2 and P2X3 receptors were used in all experiments, and provided by 
Afferent Pharmaceuticals Ltd.  Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
with 4.5g/L glucose, 4mM L-glutamine, 50 IU/mL penicillin, 50 µg/mL streptomycin and 10% 
(v/v) FBS.  Cells were cultured in the presence of either G418 (P2X2), puromycin (P2X3) or 
G418 plus puromycin (P2X2/3) selection antibiotics.  Cells were maintained at 37oC and 5% 
CO2. 
 
Patch-clamp electrophysiology 
 
Cells were resuspended at 1x106 cells/mL in solution containing (mM): NaCl, 140; KCl, 4mM; 
MgCl2, 1; CaCl2, 2; D-glucose, 5 and HEPES, 10; pH7.4).  Whole-cell planar patch-clamp was 
conducted using a Nanion port-a-patch system fitted with an 8-valve gravity fed perfusion 
panel.  The time for total solution exchange was <150ms.  Internal solution contained (mM): 
CsF, 120; NaCl, 10; MgCl2, 2; HEPES, 10; pH7.2.  Following gigaseal formation, all 
recordings were performed in external solution containing (mM): NaCl, 155; KCl, 3; MgCl2, 
1; CaCl2, 1.5; HEPES, 10; pH7.4.  Acquisition protocols were run using HEKA Patchmaster 
software (RRID: SCR_000034) and a HEKA EPC 10 amplifier.  Data was sampled at 1 kHz 
and filtered at 10 kHz.  Cells were held at -80mV in all experiments.  All recordings were 
performed at room temperature (21 – 23oC). Tau values () were calculated by fitting a single 
exponential decay curve to the desensitisation phase of current traces using Origin Pro software 
(version 2016; Originlab). 
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Animals 
 
5-7 week old female Sprague-Dawley rats (150-180g) (RRID:RGID_10395233) were obtained 
from the Beijing Vital River Company.  Animals were housed at 22 ( 3oC) with 12 hours of 
fluorescent lighting per day and food and water available ad libitum.  Animals were kept for 
one week prior to the start of experiments, health checked and randomly assigned to groups.  
Experiments began when animals were 6-8 weeks old (180-220g).  MK-7264, naproxen and 
gabapentin were dissolved in 0.5% (w/v) sodium carboxymethyl cellulose (Sigma) and 
administered by oral gavage at 5mL/kg. 
 
Complete Freund’s Adjuvant (CFA) inflammatory hyperalgesia 
 
The CFA model of inflammation leads to edema as well as mechanical allodynia of the injected 
paw (Stein et al., 1988).  50µL of CFA (Chondrex) was injected into left hind paw subplantar 
7 days prior to experimentation.   
 
Mono-idoacetate (MIA) induced osteoarthritis 
 
Mono-iodoacetic acid is an inhibitor of glyceraldehyde-3-phosphate dehydrogenase causing 
the death of chondrocytes, and histological and pathophysiological changes observed in 
osteoarthritis (Bove et al., 2003).  50µL of 0.9% normal saline containing 3mg MIA (Sigma) 
was injected through the patellar ligament into the right hind knee.  The injection was 
conducted under isoflurane anaesthesia 13 days prior to experimentation. 
 
Spared nerve injury (SNI) neuropathic pain model 
 
The spared nerve injury model induces increased mechanical and thermal sensitivity of the 
treated paw, mimicking clinical neuropathic pain (Decosterd & Woolf, 2000). The sciatic nerve 
and its three terminal branches (sural, common peroneal and tibial nerves) were exposed by 
skin incision on the lateral surface of the thigh and by sectioning the biceps femoris muscle of 
the left lateral leg.  The peroneal and tibial nerve were ligated and 42 mm of the distal nerve 
stump was axotomized followed by muscle and skin closure. The sural nerve was not ligated 
and remained intact. Surgery was conducted under anaesthesia 10 days prior to 
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experimentation.  Anaesthesia was induced using 5% isoflurane and maintained at 3% 
isoflurane with a gas flow of 1L/min using a precision vaporizer. The level of anaesthesia was 
monitored by heart rate, respiratory rate, temperature and pedal reflex.  Animals received post-
operative analgesia via subcutaneous injection of carprofen (5mg/kg) for up to 72 hours.  For 
sham animals, the sciatic nerve was exposed via a skin incision on the lateral surface of the 
thigh followed by sectioning of the biceps femoris muscle, but the nerve was not axotomized.  
Post-operative analgesia was provide for sham animals as for animals undergoing sciatic nerve 
axotomy. 
 
Von Frey filaments testing for mechanical allodynia 
 
The paw withdrawal threshold was measured by applying Von Frey filaments (Bioseb) of 
increasing force, perpendicularly to the plantar surface of the hind paw of the treated limb.  
Following acclimatisation, rats were allowed to stand on mesh and filaments were applied from 
beneath.  The average of 2-3 repeated stimuli was taken as the withdrawal threshold.  
Experimenters were blinded to drug treatments. 
 
Static weight bearing test for joint discomfort 
 
Weight redistribution between hind paws was measured using a weight balance changing 
instrument (Bio-medical, USA).  Weight distribution (g) is calculated as contralateral limb 
minus ipsilateral limb weight bearing, hence the difference diminishes as hyperalgesia is 
reduced.  Average weight bearing was measured over a 10 s period.  Experimenters were 
blinded to drug treatments.  
 
Pharmacokinetic profiling 
 
Rats received a single oral dose of MK-7264 and a single blood sample was taken from each 
animal by the retro-orbital route for a given time point.  Retro-orbital sampling was performed 
under general anaesthesia.  General anaesthesia was induced by intraperitoneal injection of 
ketamine (80 mg/kg) and xylazine (10 mg/kg). The level of anaesthesia was monitored by heart 
rate, respiratory rate, temperature and pedal reflex.  Following blood sampling, animals were 
not recovered from general anaesthesia and sacrificed by CO2 asphyxiation.  MK-7264 
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quantification was determined by liquid chromatography-tandem mass spectrometry (API 
4000 QTrap, Applied Biosystems). 
 
Data and statistical analysis 
 
All statistical analysis was performed using Origin Pro (version 2016; Originlab), unless 
otherwise stated. The threshold for statistical significance was P<0.05 throughout. Data was 
first tested with a Shapiro-Wilk test for normality and Levene’s test for equality of variance. 
For antagonist IC50 datasets, the normalised response was plotted against Log10 antagonist 
concentration and fitted with a modified Hill Equation as below:  
 
𝑌 = 𝑆𝑡𝑎𝑟𝑡 + (𝐸𝑛𝑑 − 𝑆𝑡𝑎𝑟𝑡)
𝑋𝑛
𝑘𝑛 + 𝑋𝑛
 
 
Where k = Michealis constant and n = number of cooperative sites.  The datasets were then 
compared with an F-test. Pairwise comparison of EC50 values generated in curve shift 
experiments was conducted using a paired sample T-test. Wash-on rate in the presence and 
absence of agonist was compared with a One-way ANOVA followed by Tukey post-hoc test. 
on and off rates were estimated by fitting a single exponential decay curve to the 
desensitisation phase of current traces: 
 
𝑌 = 𝐴 × exp (
−𝑥
𝑡
) + 𝑌0 
 
Where Y0 = offset, A = amplitude and t= time constant.  of desensitisation and residual current 
data was compared with a Kruskal-Wallis ANOVA followed by Dunn’s post hoc test.  
Analyses of paw withdrawal (Von Frey filaments) and static weight bearing were conducted 
with a two-way repeated measures ANOVA.  The two factors were (A) time of measurement 
after drug treatment (within groups measure) and (B) drug treatment (between groups 
measure).  Where significant interactions were detected, a subsequent Fisher least significant 
difference post-hoc test was used to compare the effect of drug treatments at individual time 
points. 
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Nomenclature of Targets and Ligands 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
 
RESULTS 
 
MK-7264 antagonises P2X3-containing receptors selectively and reversibly 
 
Human P2X3 expressed in 1321N1 cells displayed rapidly desensitising (millisecond) agonist 
evoked inward currents that recover slowly (Figure 1A).  Complete recovery for responses to 
meATPwas achieved using an interval of 4 minutes between agonist application (Figure 
1A).  P2X2/3 mediated currents were isolated in 1321N1 co-expressing P2X2 and P2X3 by 
using meATPwhich does not activate P2X2 homomers.  In some cells, initial responses 
in 1321N1 co-expressing P2X2 and P2X3 to meATPevoked mixed P2X3 (transient, 
rapidly desensitising) and P2X2/3 (slowly desensitising) responses, however the contribution 
of P2X3 homomer responses was lost after several meATPapplications at 30s intervals 
leaving P2X2/3 currents for further investigation (Figure 1B).  MK-7264 could potently inhibit 
P2X3 and P2X2/3 currents in a reversible and concentration-dependent fashion (Figures 1A 
and 1B). No effect of 10μM MK-7264 on human P2X2 currents was observed (N=5) (Figure 
1C).  The half-maximal concentration of MK-7264 antagonism at P2X3 and P2X2/3 receptors 
was 15359nM (N=5) and 22047nM (N=5) (Figure 1D), respectively. These were found to 
be significantly different by an F-test (F = 11.74, p<0.05). Measurements were made for 
reduction in peak and steady-state currents for P2X3 and P2X2/3 respectively.  The Hill 
coefficient for MK-7264 concentration inhibition was 1.00.4 for P2X3 and 1.00.2 for 
P2X2/3, indicating MK-7264 acts in a non-cooperative manner.  Antagonism of human P2X3 
receptors using a submaximal MK-7264 concentration (300nM; approximate IC70) was not 
surmounted by increasing the concentration of meATPagonist (Figure 1E), indicating 
MK-7264 acts independently of agonist concentration to block P2X3.  In addition to 
suppression of response maxima, MK-7264 also significantly reduced meATPpotency 
(EC50 1.00.1µM vehicle versus 6.01.5µM with 300nM MK-7264; N=5, paired sample T-test 
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p<0.05).  These data suggest MK-7264 is a negative allosteric modulator of the human P2X3 
receptor.      
 
Onset and offset of MK-7264 action 
 
Due to the prolonged recovery time required and rapid intrinsic desensitisation of P2X3 
receptors, the slowly desensitising and rapidly recovering P2X2/3 receptor was used to quantify 
wash-on and wash-off rates of MK-7264.  Agonist applied for 2s every 30s allowed for 
complete recovery of the P2X2/3 response, we therefore applied meATP every 30s whilst 
bath perfusing a maximal concentration of MK-7264 until steady-state inhibition of the P2X2/3 
current was achieved (Figure 2A and 2B).  To quantify wash-off, vehicle was bath perfused 
following a period of steady-state inhibition and recovery monitored by agonist application 
every 30s until steady-state response were obtained (Figure 2B).  For all wash-on and wash-
off experiments, the mean current (1-2 s from onset) was then normalised against the vehicle 
control response.  Exponential decay curves were fitted to individual data sets and on and off 
derived from curve time constants (Figure 2B).  The concentration-dependency of MK-7264 
on and off are given in Table 1.  The on rate decreased with increasing concentrations of MK-
7264 ranging between 12 – 360s for the concentration range 100nM – 3µM.  The off  value 
increased with decreasing concentrations of MK-7264.    
 
MK-7264 action before and during agonist application 
 
The slow intrinsic desensitising properties of P2X2/3 currents provided the opportunity to 
investigate the effects of rapid MK-7264 application to activated channels.  In these 
experiments, currents were initiated by rapid 2s perfusion of meATP, quickly followed by 
combined rapid perfusion of meATPand MK-7264 allowing the effect of MK-7264 on 
the steady-state current to be quantified (Figure 2C).  The current magnitude was quantified 
every 5s following MK-7264 co-application.  We observed that the on rate of inhibition by 
MK-7264 was significantly greater following application to the closed versus open channel 
(Figure 2D), with MK-7264 inhibiting the response by 832% compared to 415% following 
a 30s perfusion prior to agonist application and during agonist application, respectively (One-
way ANOVA F = 45.94, p = <0.05, followed by Tukey post hoc test) (Figure 2A vs Figure 
2D). 
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Changes in P2X3 receptor desensitisation 
 
MK-7264 antagonism of human P2X3 was associated with a slowing of the second phase of 
desensitisation that was relieved upon agonist wash-off (Figure 3A).  This apparent slowing 
of desensitisation kinetic of the response was different from control response which decayed 
to baseline during agonist application (Figure 3A).  The desensitisation phase of P2X3 after 
MK-7264 exposure consists of a rapid phase (~200ms) which is characteristic of P2X3 and 
appears unchanged apart from the reduction in magnitude, followed by a slower phase with 
shallow gradient dependent upon MK-7264 concentration.  This prolonged desensitisation 
effect of MK-7264 washed-off at a similar rate to the inhibition of peak response (Figure 3B).  
The prolonged desensitisation phase is shallow and not well fit by a single exponential curve 
to calculate a  value, and therefore a curve was fitted 250-750ms after the onset of agonist 
response to estimate the rate of this phase (Figure 3A and 3C).  MK-7264 at 1µM significantly 
decreased the rate of desensitisation from 20611ms to 6.63.5s (N=6; Kruskal-Wallis 
ANOVA followed by Dunn’s post hoc p<0.05 versus vehicle control), respectively. The 
residual current at one second after onset of agonist response was measured and shown as a 
fraction of peak current in Figure 3D. The residual current increased with antagonist 
concentration and was significantly different from the vehicle control at 300 nM and 1 µM 
(Kruskal-Wallis ANOVA followed by Dunn’s post hoc test, p <0.05). 
 
Efficacy of MK-7264 in rat model of inflammatory hyperalgesia 
 
MK-7264 and the non-steroidal anti-inflammatory naproxen were tested for their ability to 
reduce mechanical sensitivity and weight-bearing discomfort in a Complete Freund’s Adjuvant 
(CFA) model of inflammatory hyperalgesia (Figure 4).  For the Von Frey measurements there 
was significant differences between the time of measurement (F = 17.6, p < 0.05), the 
treatments (F = 24.4, p < 0.05) and the interaction between these factors (F = 5.03, p <0.05).  
For weight bearing measurements there were significant differences between the time of 
measurement (F = 44.29, p <0.05), the treatments (F = 28.8, p < 0.05) and the interaction 
between these factors (F = 9.97, p <0.05).  Fisher least significant difference post hoc test 
indicated that both naproxen and MK-7264 at 20 mg/kg and 30 mg/kg respectively, 
significantly reduced mechanical sensitivity (increased paw-withdrawal) threshold compared 
to vehicle control, 1 and 3 hours after dosing and to a comparable level (N=10; p<0.05 for both 
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treatments versus vehicle control) (Figure 4A).  The maximum reduction for both treatments 
was observed at 3 hours, where the mean withdrawal threshold was 6.00.6g, 8.20.9g and 
8.10.5g for vehicle, naproxen and MK-7264, respectively.  Withdrawal threshold was 
13.30.2g (N=20) in naïve control animals. MK-7264 was also efficacious in reducing weight-
bearing discomfort at 1 and 3 hours after dosing (Figure 4B).  The maximum effect of MK-
7264 (30 mg/kg) was observed at 3 hours and similar to that of naproxen (20 mg/kg), where 
difference in weight bearing between contralateral and ipsilateral limbs was 556g, 354g and 
344g for vehicle control, MK-7264 and naproxen (N=10; p<0.05 for all treatments versus 
vehicle control), respectively.  These values are compared to 5.80.8g (N=12) for sham 
animals.  Individual differences detected with a Fisher least significant difference post-hoc test 
are shown in Figure 4. 
 
Efficacy of MK-7264 in rat model of osteoarthritis pain 
 
MK-7264 in vivo efficacy was investigated further to provide relief from mechanical 
hypersensitivity in a model of monoiodoacetate (MIA)-induced osteoarthritis.  In these 
experiments three doses of MK-7264 (3, 10 and 30 mg/kg) were compared with naproxen (20 
mg/kg) and vehicle control (Figure 5A). For the Von Frey measurements there were significant 
differences between the time of measurement (F = 157.27, p < 0.05), the treatments (F = 87.99, 
p < 0.05) and the interaction between these factors (F = 30.37, p <0.05).  For weight bearing 
measurements there were significant differences between the time of measurement (F = 44.8, 
p <0.05), the treatments (F = 14.35, p < 0.05) and the interaction between these factors (F = 
4.96, p <0.05).  A Fisher least significant difference post hoc test indicated that naproxen and 
MK-7264 at 10 and 30 mg/kg significantly increased the paw-withdrawal threshold 1 and 3 
hours after administration (Figure 5A).  The maximum effect of all drug treatments was 
observed at 3 hours following administration, where the paw-withdrawal threshold for 
6.40.7g, 10.90.6g, 9.60.8g and 10.70.8g for vehicle control, naproxen, and MK-7264 at 
10 mg/kg and 30 mg/kg, respectively (N=10; p<0.05 for all treatments versus vehicle control).  
Withdrawal threshold was 13.30.2g (N=20) in control animals. MK-7264 at 3 mg/kg produced 
no significant effect over vehicle control (Figure 5A).  Similar effects of MK-7264 dosing 
were observed in reducing the difference in weight bearing between contralateral and ipsilateral 
limbs in the osteoarthritis model at 1 and 3 hours following administration (Figure 5B).  
Naproxen and MK-7264 (30 mg/kg) significantly reduced the difference in weight bearing 
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between contralateral and ipsilateral limbs to 24.24.1g and 24.53.1g, respectively, compared 
to 35.94.1g in vehicle control (N=10; p<0.05 for treatments versus vehicle control).  These 
values are compared to 6.80.5g (N=10) for sham animals. Individual differences detected with 
a Fisher least significant difference post-hoc test are shown in Figure 5. 
  
Efficacy of MK-7264 in rat neuropathic pain model 
 
Finally we sought further verification for the in vivo efficacy of MK-7264 in a rat model of 
neuropathic pain (Figure 6).  Hypersensitivity was assayed by measurement of paw-
withdrawal threshold and weight-bearing discomfort.  In a Phase I experiment to determine the 
efficacy of MK-7264 in reducing hypersensitivity, animals were administered with either 
vehicle control, gabapentin (100mg/kg) as a positive control, or MK-7264 at either 10 or 30 
mg/kg.  Paw-withdrawal threshold and weight-bearing discomfort were measured 1, 3 and 8 
hours following administration.  For Von Frey assessment of paw-withdrawal threshold, there 
were significant differences between the time of measurement (F = 22.99, p < 0.05), the 
treatments (F = 11.75, p < 0.05) and the interaction between these factors (F = 2.18, p <0.05) 
(Figure 6A).  Nerve injury produced hypersensitivity as assessed by paw-withdrawal.  
Thresholds were 7.40.5g (N=10) for animals that underwent nerve injury, compared to 
13.30.2g (N=20; p <0.05) for sham surgery animals.  Gabapentin (100 mg/kg), and MK-7264 
administered at 10 mg/kg and 20 mg/kg all significantly increased paw-withdrawal threshold 
compared to vehicle control at 1 and 3 hours post administration (Figure 6A).  Following phase 
I experiments, a second dosing regimen was undertaken to test for drug tolerance.  In these 
experiments (termed phase II), animals were repeatedly dosed for 12 hour intervals and drug 
efficacy re-evaluated at the same timepoints as phase I starting at day 5.5.  For the Von Frey 
measurements there were significant differences between the time of measurement (F = 22.13, 
p <0.05), the treatments (F = 49.61, p < 0.05), and the interaction between these factors (F = 
6.57, p<0.05).  After the 5.5 day repetitive dosing region, administration of gabapentin (100 
mg/kg) and MK-7264 (30 mg/kg) significantly increased paw-withdrawal threshold for 8 hours 
post administration compared to administration of vehicle control (Figure 6B).  The efficacy 
of MK-7264 at 10 mg/kg diminished significantly after 3 hours post administration (Figure 
6B).    
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For Phase I weight-bearing discomfort measurements, there were significant differences 
between the time of measurement (F = 25.64, p <0.05) and the treatments (F = 14.35, p < 0.05), 
but no significant interaction between these factors (Figure 6C).  Nerve injury produced 
hypersensitivity as assessed by weight-bearing discomfort.   Difference in weight bearing 
between contralateral and ipsilateral limbs were 51.17.8g (N=10) for animals that underwent 
nerve injury, compared to 5.80.8g (N=12; p <0.05) for sham surgery animals.  In Phase I 
experiments, administration of gabapentin (100 mg/kg) or MK-7264 at 10 mg/kg and 30 mg/kg 
significantly reduced the difference in weight bearing between contralateral and ipsilateral 
limbs up to 3 hours post administration compared to administration of vehicle control (Figure 
6C).  In phase II experiments of weight-bearing discomfort, there were significant differences 
between the time of measurement (F = 4.21, p <0.05) and drug treatment (F = 12.68, p <0.05).  
Administration of gabapentin (100 mg/kg) and MK-7264 at 30 mg/kg caused a sig significant 
reduction in the difference in weight bearing between contralateral and ipsilateral limbs up to 
3 hours post administration compared to administration of vehicle control (Figure 6D).  MK-
7264 at 10 mg/kg reduced weight-bearing difference up to 1 hour but its effects had diminished 
by 3 hours (Figure 6D). 
 
MK-7264 blood plasma concentration following dosing in vivo in rats 
 
Rats received a single oral doses of MK-7264 and plasma concentrations were determined for 
different dosages at 0, 1 and 3 hours after dosing to determine the pharmacokinetic profile 
(Figure 7).  The plasma concentration following a single oral dose of MK-7264 was determined 
post administration by orbital blood sampling to correlate with exposure times that proved 
efficacious in inflammatory pain models.  After 3 hours, plasma concentrations ranged from 
250 – 1087nM (mean 605257nM; N=10) for 10 mg/kg, 365 – 1882nM (mean 1027597nM; 
N=10) for 20 mg/kg, and 1194 – 3396nM (mean 2077775nM; N=10) for 60 mg/kg. 
 
DISCUSSION 
 
These studies reveal nanomolar potency of the human P2X3 and P2X2/3 receptor antagonist 
MK-7264, with marginal selectivity for P2X3 over recombinant P2X2/3 receptors.  Both P2X3 
and P2X2/3 are expressed by somatosensory neurons (Chen et al., 1995; Lewis et al., 1995; 
Bradbury et al., 1998), and selective antagonism of these receptors reduces nocifensive 
  
This article is protected by copyright. All rights reserved. 
responses in several rat models of pain (Jarvis et al., 2002; McGaraughty et al., 2003; Kaan et 
al., 2010; Grishin et al., 2010).  Our pharmacological analysis demonstrates that the action of 
MK-7264 is insurmountable by increasing agonist concentration.  Like its structural relative 
AF-353 (Gever et al., 2010), MK-7264 attenuated the response maxima in addition to 
decreasing agonist potency.  This demonstrates that MK-7264 does not act as a pure non-
competitive antagonist, but rather exerts its antagonism through negative allosteric modulation 
of the P2X3 receptor.  The allosteric nature of MK-7264 is supported by the recent publication 
of the human P2X3 homomeric receptor with MK-7264 bound (Wang et al., 2018).  
Radioligand binding studies with AF-353 (Gever et al., 2010) suggest that this series of 
compounds does not alter agonist affinity but rather negatively modulates efficacy.  The 
proposed MK-7264 binding site resides within an inter-subunit interface created by the lower 
body and dorsal fin of one P2X3 subunit and the lower body domain of an adjacent P2X3 
subunit.  This site is distinct from the orthosteric ATP binding site in P2X receptors (Mansoor 
et al., 2016) and supportive of MK-7264 acting allosterically.  Interestingly, the key residues 
proposed to form the MK-7264 binding site by Wang et al (2018) have a high degree of 
physicochemical conservation across all human P2X receptors.  Our observation that human 
P2X2 homomeric receptors are insensitive to MK-7264 suggests that the presence of these 
residues alone is not sufficient to convey sensitivity, rather the spatial positioning of these 
residues is important.  This hypothesis is supported by in silico measurements of the spatial 
distribution of these key residues indicates that they are spaced further apart in the zebrafish 
P2X4 crystal structure (Kawate et al., 2009), which mostly shares the key MK-7264 binding 
residues with human P2X3 but they are spatially further apart.  The stoichiometry of native 
P2X2/3 remains undetermined, but at least one P2X3-P2X3 interface may exist and convey 
MK-7264 sensitivity to the P2X2/3 heteromer, though with slightly less sensitivity compared 
to P2X3 homomeric receptors.  It is also possible that a P2X2-P2X3 interface creates a suitable 
binding pocket. 
 
The wash-on rate of MK-7264 to the P2X2/3 receptor was concentration-dependent and 
significantly attenuated in the presence of agonist, and as with AF-353, the high compound 
potency is due to comparatively slow on and off rates (Gever et al., 2010).  This is in contrast 
to rapid rates of other P2X receptor antagonists such as PPADS (Li, 2000), TNP-ATP and 
suramin (Spelta et al., 2002).  The disparity in MK-7264 wash-on rate in the absence (presumed 
predominantly closed channel population) and presence (presumed predominantly 
open/desensitising channel population) indicates that MK-7264 exerts its effects more rapidly 
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at agonist unbound (closed) channels.  This is in contrast to PPADS which was found to bind 
three times more rapidly to the open over the closed P2X2/3 receptor (Spelta et al., 2002). The 
crystal structure of human P2X3 in the open and closed confirmation (Mansoor et al., 2016) 
indicates that the MK-7264 binding pocket undergoes a dynamic change upon ATP binding, 
whereby the dorsal fin domain shifts upwards and the left fin moves downwards.  This 
structural transition disrupts the MK-7264 binding pocket and is the likely molecular basis for 
the disparity between MK-7264 on-rates in the presence and absence of agonist.  A further 
pharmacological characteristic of MK-7264 is a slowing of the rate of desensitisation.  The 
reason for this slowing of desensitisation and propagation of a residual current is not known, 
but it could be that MK-7264 binding interferes with the transition of open to desensitised 
channel.  An alternative explanation may be that partial antagonist saturation of the receptor 
leads to a non-desensitising conductance or sub-conductance state.  The observation that this 
effect is relieved upon agonist wash-off indicates that it is an agonist-dependent process.  
Although mechanistically interesting, this slowing of desensitisation observed under conditions 
of voltage-clamp does not prevent the therapeutic activity of MK-7264 in humans (Abdulgawi 
et al., 2015) or in rat models.  MK-7264 has a relatively slow time course of action in the in 
vivo rat models employed in this study.  The slow on/off rates at the receptor level cannot 
completely account for this observation.  The pharmacokinetics of MK-7264 following oral 
dosing are likely to be a major contributor to the slow onset of in vivo efficacy.  A sufficiently 
high concentration of MK-7264 to achieve complete blockade of P2X3 (low micromolar) is 
achieved by 1 hour in doses in excess of 20 mg/kg (but not at 10 mg/kg) and maintained until 
at least 3 hours.  The time taken for plasma concentrations to peak to a point where P2X3 
receptors are maximally blocked in in vitro experiments is likely to account for why the greatest 
in vivo efficacy is not observed until 3 hours after dosing. 
 
ATP is released by mammalian cells under inflammatory conditions, both passively from cells 
undergoing lysis, and actively via vesicular and channel mediated processes (Dosch et al., 
2018).  The expression of P2X3 on somatosensory neurons therefore makes it a potential target 
for a range of peripheral sensory disorders (Ford, 2012).  In both the Complete Freund’s 
adjuvant model of inflammatory hyperalgesia and the monosodium iodoacetate injection model 
of osteoarthritis, 30 mg/kg MK-7264 acted with the same efficacy as 20 mg/kg naproxen, 
indicating MK-7264 provides relief from inflammatory and osteoarthritic pain in these models.  
In the spared nerve injury model of neuropathic pain, acute MK-7264 dosing could relieve pain 
with the same efficacy as 100 mg/kg gabapentin.  After chronic dosing with MK-7264, the 
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response to acute noxious stimuli (Von Frey) was reduced at all time points tested, but this did 
not translate to a prolonged reduction in weight bearing discomfort.  These data indicate that 
MK-7264 works efficaciously to reduce pain hypersensitivity in vivo.  MK-7264 was as 
effective as current treatments and continued to show efficacy after repeated dosing in the 
neuropathic pain model, suggesting lack of tolerance.  Finally, the plasma concentrations of 
MK-7264 at 3 hours post oral administration suggest high bioavailability, with low micromolar 
plasma concentrations achieved at 20 and 60 mg/kg.  These concentrations are sufficient to 
reduce P2X3 and P2X2/3 activity by 75-95% in vitro and significantly reduce rat nocifensive 
responses and discomfort in vivo. MK-7264 is peripherally restricted (Pijacka et al., 2016) and 
therefore the in vivo effects are not the result of centrally mediated mechanisms.  ATP released 
from damaged or inflamed tissues can activate P2X receptors expressed on primary afferent 
neurons.  The resulting depolarization can initiate action potentials that are interpreted centrally 
as pain (North, 2004).  This is also observed in humans where intracutaneous injections of ATP 
elicited discharge of afferent neurons innervating the peroneal nerve (Hilliges et al., 2002).  
P2X3 has very limited expression, predominantly located on afferent neurons, including those 
innervating the skin, viscera, and knee joint (Bradbury et al., 1998; Teixeira et al., 2017).  
Inhibition of P2X3-dependent action potential of afferent neurons innervating peripheral tissue 
and nerves is therefore the likely mechanism mediating the in vivo effects of MK-7264 in pain 
models. 
 
In summary, MK-7264 is a first-in-class, selective, reversible and orally bioavailable P2X3 and 
P2X2/3 receptor antagonist with in vivo efficacy for the relief of inflammatory, osteoarthritic 
and neuropathic pain.  MK-7264 likely exerts its antagonism via negative allosteric 
modulation. 
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Figure 1 MK-7264 activity at human P2X2, P2X3 and P2X2/3 receptors. (A-C) shows 
representative concatenated traces of whole-cell patch-clamp recordings for human P2X3 
(A), P2X2/3 (B) and P2X2 (C) receptor currents in 1312N1 stably transfected cells.  Fully 
recovered P2X3 currents are evoked by 10µM meATPapplied for 1s every 4 mins, and 
10µM meATPapplied for 2 s at 30 s intervals for P2X2/3 currents.  P2X2 currents are 
evoked by 10µM ATP every 4 mins.  MK-7264 was applied 4 mins, 30 s and 4 mins prior to 
agonist application for P2X3 (1µM), P2X2/3 (1µM) and P2X2 (10µM) receptors, 
respectively.  Agonist application is indicated by the perfusion bar.  Currents shaded in grey 
are in the presence of MK-7264.  (D) MK-7264 concentration-inhibition curve at human 
P2X3 (closed circles) and P2X2/3 receptors (open circles) (N=5). Data sets were compared 
with an F-test and found to be significantly different from one another (F = 11.74, P = 0.018) 
(E) Effect of MK-7264 on meATPconcentration-response curve at P2X3.  Currents are 
in the presence of 300nM MK-7264 (open circles) or vehicle control (closed circles) (N=6).  
MK-7264 applied for 4 mins prior to agonist application. EC50 values were compared with a 
paired-sample T-test and found to be significantly different (P = 0.018). The holding potential 
was -80mV for all experiments. 
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Figure 2 MK-7264 antagonism has different on-rates when applied before or during 
agonist application at the human P2X2/3 receptor.  (A) Representative trace showing 
effect of a 30 s preincubation with 3µM MK-7264 on currents evoked by 10µM 
meATPat human P2X2/3 receptors.  Agonist application is indicated by the perfusion 
bar.  Currents shaded in grey are in the presence of MK-7264. (B)  The effect of varying 
preincubation time of MK-7264 (3µM) on antagonism of P2X2/3 responses (10µM 
meATP, 2s) (closed circles; N=7), and the effect of wash-off time on response recovery 
following maximal antagonism (open circles).  Time constants ( values) are calculated from 
single exponential curve fits.  Data is normalised to the control response prior to MK-7264 
application.  (C)  Representative trace showing effect of rapid co-application of agonist and 
MK-7264.  Responses were evoked with 10µM meATPfor 2s followed by co-
application with 3µM MK-7264 or vehicle.  (D)  Relationship between magnitude of P2X2/3 
antagonism and wash on time during meATPapplication (open circles) and before 
application (closed circles).  Data is normalised to response prior to MK-7264 application 
(closed circles) or the magnitude of response at the same time point in the presence of vehicle 
(open circles) (N=5). Datasets were compared with a One-way ANOVA (F = 45.95, P <0.05) 
followed by Tukey post hoc test. 
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Figure 3 MK-7264 antagonism of human P2X3 receptor is associated with an onset of 
slowed desensitisation.  (A) Representative trace showing a diminished peak response and 
appearance of slow desensitisation are associated with MK-7264 antagonism.  (B) 
Representative superimposed trace showing time-dependent recovery of P2X3 fast 
desensitisation following MK-7264 (300nM) wash-off.  Agonist applied every 4 mins.  (C)  
Relationship between MK-7264 concentration and the rate of desensitisation.  Time constants 
( values) are derived from single exponential curves fitted to the desensitisation phase 250-
750ms after the peak response. Tau values were compared with a Kruskal-Wallis ANOVA (P 
<0.0001) followed by Dunn’s post hoc test N=6.  (D) The change in shape of the current 
following MK-7264 antagonism quantified as a fractional response (residual current, 1s after 
onset of agonist response over peak current) and compared with a Kruskal-Wallis ANOVA 
followed by Dunn’s post hoc test.  * P<0.05 versus control response; N=7. 
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Figure 4 MK-7264 efficacy in a rat model of inflammatory hyperalgesia.  Complete 
Freund’s adjuvant hindpaw injection model of inflammatory hyperalgesia.  (A) Effect of 
single oral dose of vehicle, naproxen or MK-7264 on paw withdrawal threshold determined 
by Von Frey filament testing (N=10). (B)  Effect of single oral dose of vehicle, naproxen or 
MK-7264 on postural equilibrium (weight bearing) of inflamed versus non-inflamed 
hindlimb (N=10). Naproxen serves as a positive control.  Sodium carboxymethyl cellulose is 
the vehicle control. Drug treatments were compared with a Two-way repeated measures 
ANOVA followed by Fisher least significant difference post hoc test. * P<0.05 versus 
vehicle control. 
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Figure 5 MK-7264 efficacy in a rat model of osteoarthritic pain.  Mono-iodoacetate 
(MIA) hind knee injection model of osteoarthritic pain. (A) Effect of single oral dose of 
vehicle and naproxen and ranging MK-7264 doses on paw withdrawal threshold determined 
by Von Frey filament testing (N=10). (B)  Effect of single oral dose of vehicle and naproxen 
or ranging MK-7264 doses on postural equilibrium (weight bearing) of injected versus non-
injected hindlimb (N=10).  Drugs were administered 13 days following MIA injection. 
Naproxen serves as a positive control.  Sodium carboxymethyl cellulose is the vehicle 
control.   Drug treatments were compared with a Two-way repeated measures ANOVA 
followed by Fisher least significant difference post hoc test.* P<0.05 versus vehicle control. 
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Figure 6 MK-7264 efficacy in a rat spared nerve model of neuropathic pain.  Sciatic 
nerve injury model induced by axotomy of peroneal and tibial nerves.  Phase I experiments 
represent single oral dosing 10 days after surgery.  Following completion of the Phase I 
dosing regimen, Phase II experiments were undertaken using oral dosing every 12 hours for 
5.5 days to test for drug tolerance. (A and B) Effect of phase I dosing (A) and phase II dosing 
(B) regimens on paw withdrawal threshold determined by Von Frey filament testing (N=10).  
(C and D) Effect of phase I dosing (C) and phase II dosing (D) regimens on postural 
equilibrium (weight bearing) of injected versus non-injected hindlimb (N=10).  Gabapentin 
serves as a positive control.  Sodium carboxymethyl cellulose is the vehicle control. Drug 
treatments were compared with a Two-way repeated measures ANOVA followed by Fisher 
least significant difference post hoc test.* P<0.05 versus vehicle control. 
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Figure 7 Plasma concentration of MK-7264 following oral dosing in rats.  Quantification of 
MK-7264 plasma concentration following oral dosing with 10 (open circles), 20 (closed 
circles) and 60 (squares) mg/kg at 0, 1 and 3 hours after dosing (N=5). Sampling from orbital 
blood. 
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Table 1 Mean τon and τoff times for MK-7264 at the human P2X2/3 receptor. Rates were 
estimated by fitting a single exponential decay to individual data sets for mean 1-2 second 
current during onset and offset of antagonist effect. Data shown is the mean ±SEM of 6 cells. 
Cells were held at -80 mV. 
 
 
MK-7264 concentration (nM) Mean τon ±SEM (s) Mean τoff ±SEM (s) 
3000 11.82 (±0.66) 113.43 (±14.42) 
1000 38.04 (±2.34) 152.95 (±14.12) 
300 176.04 (±27.59) 183.04 (±24.14) 
100 359.78 (±141.98) 258.11 (±45.96) 
 
 
 
 
